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Modern clinical practice relies on evidence-based medicine (EBM) and evidence-based guidelines
(EBGs). The critical evaluation of EBGs value is therefore an essential step to further improve clinical
practice. In our opinion, correlating levels of evidence and grades of recommendation can be an easy
tool to quickly display internal consistence of EBGs.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Evidence-based medicine (EBM) has been deﬁned as the ‘‘inte-
gration of best research evidence with clinical expertise and patient
values’’. The ﬁrst historical descriptions of EBM date back to the
beginning of 1990s, when the work of Gordon Guyatt, David Sackett
and others established the emerging methodologies of EBM [8,20].
The main products of EBM are evidence-based guidelines
(EBGs), ‘‘systematically developed statements to assist practi-
tioner and patient decision about appropriate health care for
speciﬁc clinical circumstances’’ [21]. EBGs indeed substantially
improve clinical care [29].
Costs, ethical concerns in placebo-controlled trials, publication
bias and a real risk of reductionism are the most emphasized
limitations of EBM. In order to overcome these limitations and
improve EBGs quality standards, different societies (among which
the World Health Organization, WHO) produced guidelines for
guidelines developers.
Preliminary steps for guideline development are evaluation of
priority settings [14], composition of an expert panel [9], manage-
ment of conﬂicts of interests [3], determination of appropriate
group processes [10], of important outcomes [22] and of which
evidences have to be included [15].. This is an open access article un
i).Then developers have to produce synthesis and presentation
of evidences [16], exposing criteria for grading evidence and
recommendations [23], integrating when possible values (e.g.
ethical considerations) and consumer involvement [24]. Next,
considerations of cost-effectiveness, affordability and resource
implications [7], of equity [17], applicability, transferability and
adaptation [25] should be included.
The ﬁnal steps are the report of guidelines recommendations
[18], the dissemination and implementation of guidelines [11]
and their evaluation [19].
Since EBGs frequently vary widely in quality [26,27], their
evaluation is very important. Updating a ﬁrst systematic review
[12,28] found 24 different EBGs appraisal tools. The Appraisal of
Guidelines for Research and Evaluation (AGREE) instrument was a
validated, easy-to-use, and transparent tool, which was interna-
tionally developed and widely accepted. It was developed through
a process of item generation, selection and scaling, ﬁeld-testing
and reﬁnement. The ﬁnal version of the instrument contained 23
items grouped into six domains: scope and purpose, stakeholder
involvement, rigor of development, clarity and presentation,
applicability, and editorial independence [2].
Despite the good review of the AGREE instruments, two
important limitations are present: although it can be used to
compare clinical practice guidelines, AGREE instrument does not
set a threshold to classify them as good or bad, and it does not
assess the quality of the evidence supporting the recommenda-
tions [29].der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Levels of evidence and respective grades of recommendation in the guidelines for the treatment of bone metastases by the Italian Society for Medical Oncology.
Topic Level of
evidence
Grade of
recommendation
1. Bisphosphonates in metastatic cancers
a. Indication: breast cancer
Efﬁcacy of bisphosphonates in reducing scheletal-related events I A
Efﬁcacy of bisphosponates in reducing pain levels and improving quality of life I A
Route of administration of bisphosphonates: endovenous vs oral I A
Efﬁcacy of zoledronic acid vs other bisphosphonates II A
b. Indication: prostate cancer N/A N/A
c. Indication: lung cancer
Efﬁcacy of bisphosphonates in reducing scheletal-related events III B
d. Indication: renal cancer
Efﬁcacy of bisphosphonates in reducing scheletal-related events III B
e. Indication: other cancers
Efﬁcacy of bisphosphonates in reducing scheletal-related events III C
f. Lenght of the therapy
Extension of treatment after the ﬁrst two years V B
Switch from oral bisphosphonate to zoledronic acid V B
g. Timing of therapy start
Therapy after radiological evidence of bone metatases in absence of sintoms V B
h. Dosage and schedule
Standard dosage and schedules suggested in clinical trials and by FDA and EMEA I A
i. Route of administration
Endovenous or oral administration, according to criteria exposed in the guideline I A
j. Multidisciplinary approach
Team-based therapeutical approach to patients affected by bone metastases V B
k. Vitamin D supplementation N/A N/A
l. Markers of bisphosphonate efﬁcacy
Role of N-terminal telopeptide III C
m. Quality of life
Control of bone pain I A
Co-analgesic effect in combination with major analgesic drugs I A
Selection of adequate bisphosphonate for quality of life and pain management I A
High-dose bisphosphonates in opioid-resistant bone pain V D
High-dose ibandronate in severe bone pain V D
Zoledronic acid role in incident pain V D
Overall effects of bisphosphonates in improving quality of life II A
2. Bisphosphonate in cancer induced bone loss
a. Diagnosis of osteoporosis in cancer patients
DEXA in the diagnosis of osteoporosis in cancer patients I A
b. Fracture risk in breast cancer patients
Evaluation of fracture risk in breast cancer patients with preserved ovarian function or in postmenopause under tamoxifen or no
ormonal treatment
I A
Evaluation of fracture risk in breast cancer patients with premature menopause due to medical/surgical therapies or in
postmenopause under aromatase inhibitor treatment
I A
Global decision algorithm, in consideration of bone mass density, age and other factors VI B
Selection of adequate bisphosphonate for cancer induced bone loss I A
Role of bisphosphonates in cancer patients bone health I A
Efﬁcacy of bisphosphonates in cancer induced bone loss I A
c. Prevention and therapy of osteoporosis in breast cancer patients
Selection of adequate bisphosphonate for prevention and therapy of osteoporosis I A
Bisphosphonates role in the prevention of osteoporosis VI B
Bisphosphonates role in the therapy of osteoporosis I A
Optimal length of therapy VI B
d. Fracture risk and osteoporosis in prostate cancer patients under androgen blockade
Fracture risk in prostate cancer patients under androgen blockade I A
Selection of adequate bisphosphonate VI B
Decision algorithm for prostate cancer patients under androgen blockade VI B
Other risk factors for osteoporosis in prostate cancer patients under androgen blockade VI B
Bisphosphonates role in the therapy of osteoporosis in prostate cancer patients under androgen blockade VI B
Optimal length of therapy VI B
Bisphosphonates role in the prevention of osteoporosis in prostate cancer patients under androgen blockade I B
3. Bisphosphonate safety
a. Renal safety
Role of bisphosphonates dosage and infusion speed on renal function II A
Bisphosphonate dosage reduction in patients with impaired renal function II A
Risk of hypocalcemia and hypomagnesemia after bisphosphonate endovenous administration II A
Endovenous ibandronate and renal safety II A
Oral ibandronate and renal safety II A
b. Osteonecrosis of the jaw
Diagnosis and treatment V C
Prevention III A
Oral surgery during endovenous bisphosphonate treatment V C
c. Rare adverse events
Ocular adverse events II B
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Table 1 (continued )
Topic Level of
evidence
Grade of
recommendation
4. Treatment of bone metastases pain
a. Pharmacological treatments
Usage of non-opiate, opiate and adiuvant drugs for pain control I A
Tramadol vs other opiate drugs in mild-moderate pain VI B
Adverse events related to analgesic treatments III C
Selection of drugs for moderate–severe pain I A
Efﬁcacy of analgesic therapy I A
5. Role of bisphosphonates in speciﬁc settings
a. Old patients and/or patients with comorbidity
Efﬁcacy of bisphosphonates in reducing scheletal-related events in old patients VI B
Efﬁcacy of bisphosphonates in reducing bone pain in old patients VI B
Role of renal function and hydration status monitoring in old patients VI B
Criteria for oral bisphosphonate selection in old patients VI B
Criteria for endovenous bisphosphonate selection in old patients VI B
Adverse gastrointestinal effects and compliance in old patients VI B
Risk of osteonecrosis of jaw in old patients VI B
b. Bisphosphonate with speciﬁc oncological treatments
Synergistic effects between chemotherapy drugs and bisphosphonates V D
6. Role of orthopedic surgery in bone metastases
a. Lesions to appendicular skeleton or pelvic and shoulder girdles
Class 1 patients: asportation of bone metastases IV B
Class 2 and 3 patients: external ﬁxation IV B
Class 4 patients: surgery only after mechanical failure or progressive pain IV B
Fracture risk of pelvic lesions IV B
Surgical treatment of pelvic lesions IV B
Bone curettage IV B
Prosthetic surgery IV B
b. Spinal metastases
Role of surgery in spinal metastases IV B
c. Spinal compression
Role of surgery in spinal compression IV B
d. Type of surgery
Complete removal of metastatic lesions IV B
Vertebroplasty/kiphoplasty in painful metastatic lesions IV B
7. Role of radiotherapy in bone metastases
a. External beams in bone metastases
Pain control in hypofractionated short vs long radiation therapy I A
Timing of radiation therapy II B
Pain control in monofractionated vs multifractionated radiation therapy I A
Monofractionated treatment of painful metastatic lesion I A
Hypofractionated treatment of painful metastatic lesion I A
Antalgic effects and complete response II B
Reirradiation feasibility III B
Reirradiation dosage III B
b. Radiotherapy in medullary compression
Therapy for good prognosis patients III C
Therapy for bad prognosis patients I A
Reirradiation in medullary compression VI C
c. Radiomethabolic therapy
Efﬁcacy of radiomethabolic therapy I A
Synergisms vs side effects of combinating chemotherapy and radiomethabolic therapy I B
Inefﬁcacy of combinating of external beam radiotherapy and radiomethabolic therapy I B
N/A: not applicable.
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not necessarily correlate, since the ﬁrst is a measure of scientiﬁc
strength and the latter of clinical utility.
Recently, an improved version of the AGREE, i.e. the AGREE II
instrument, has been released [4,5], partly overcoming the previous
limitations. Indeed, the introduction of the new item assessing
the description of strengths and limitation of the body of evidences
can be considered as a precursor for clinical validity or appropriate-
ness of the recommendations. The authors recognize the value of this
point, in fact they state that the AGREE consortium is targeting this
area as its next priority for further study in the AGREE A3
initiative [6].
In our opinion, correlating level with grade could be a valid
way to integrate the AGREE II instrument and quickly display the
internal consistence of EBGs.2. Material and methods
The guidelines for the treatment of bone metastases by the
Italian Society for Medical Oncology (AIOM) are based on: European
Society for Medical Oncology (ESMO) guidance on the use of
bisphosphonates in solid tumors [1] and on the management of
aromatase inhibitor-associated bone loss [13]; Cochrane network
reviews; critical review of the literature updated to June 2009.
The topics covered by the AIOM guidelines are use of
bisphosphonates in metastatic cancers; use of bisphosphonates in
the prevention and treatment of cancer treatment induced
bone loss; safety of bisphosphonates use; treatment of bone
metastases pain; role of bisphosphonates in speciﬁc settings; role
of orthopedic surgery in bone metastases; role of radiotherapy in
bone metastases.
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were provided according to the recommendations of the Italian
Centre for the Evaluation of the Efﬁcacy of Health Assistance
coordinated by the Italian National Health Institute (Istituto
Superiore di Sanita) and are presented in Table 1.
We performed an analysis of levels of evidence and respective
grades of recommendations of the guidelines for treatment of
bone metastases by AIOM.
Spearman’s rank correlation coefﬁcient was calculated per
each topic of the guidelines, a p value o0.05 was considered
statistically signiﬁcant. The ﬁnal correlation was performed
using a linear regression model (GraphPad Prims version 5.04,
La Jolla California USA); linear r2 value was reported to weight
the results and a p value o0.05 was considered statistically
signiﬁcant.3. Results
The results of our analysis showed a statistically signiﬁcant
correlation between the levels of evidence and the grades of
recommendation in the following topics: use of bisphosphonates
in metastatic cancers (po0.01); use of bisphosphonates in the
prevention and treatment of cancer treatment induced bone
loss (po0.01); safety of bisphosphonates use (po0.05); role of
bisphosphonates in speciﬁc settings (po0.01); role of orthopedic
surgery in bone metastases (po0.0001); role of radiotherapy in
bone metastases (po0.01).
Finally, a statistically signiﬁcant correlation was also found
considering all the levels of evidence and grades of recommenda-
tion together regardless of the division in topics (r2¼0.4454,
po0.0001; Fig. 1).4. Discussion
EBGs represent a milestone for modern evidence-based clinical
practice; they indeed substantially improve clinical care [29].
Nevertheless, EBGs frequently vary widely in quality [26,27], thus
their evaluation is of critical importance. Among several evalua-
tion tools, the AGREE instrument is the most widely used, even
though it has known limitations, i.e. the impossibility to classify
EBGs as good or bad and to assess the quality of the evidences
supporting the recommendations.
In order to overcome these limitations, we performed an
analysis of levels of evidence and respective grades of recom-
mendations of the guidelines for treatment of bone metastases by
AIOM. In six out of seven topics, levels of evidence and respectiveFig. 1. Correlation between levels of evidence and respective grades of recom-
mendation in the guidelines for the treatment of bone metastases by the Italian
Society for Medical Oncology regardless of the division in topics.grades of recommendations signiﬁcantly correlated. Moreover, a
statistically signiﬁcant correlation was also found considering all
the levels of evidence and grades of recommendation together
regardless of the division in topics. These results indicate that
the authors of the guidelines worked scientiﬁcally with a correct
approach and that these guidelines are likely to be adherent with
modern medical literature.
However, we cannot exclude that a signiﬁcant correlation for
some topics could be due to low levels of evidences from medical
literature and consequent low grades of recommendations.
Moreover, the lack of concordance in speciﬁc items could also
derive from the impossibility for the physicians to prescribe a
speciﬁc drug in a speciﬁc setting (i.e. low grade of recommenda-
tion) due to the delayed approval by regulatory agencies (e.g. FDA,
EMA) even in presence of adequate scientiﬁc literature (i.e. high
level of evidence).
The critical evaluation of EBGs is an underestimated issue
in current clinical practice. Moreover, speciﬁc methodological
aspects for the evaluation of EBGs are of increasing interest in
the medical oncology community. Here we provide clinicians
with a quick tool to evaluate the internal consistence of EBGs.
Further analysis should conﬁrm the reliability of this method,
which could be easily implemented in future EBGs.References
[1] Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations
of an international expert panel. Annals of Oncology 2007;19:420–32.
[2] AGREE Collaboration. Development and validation of an international apprai-
sal instrument for assessing the quality of clinical practice guidelines: the
AGREE project. Quality and Safety in Health Care 2003;12:18–23.
[3] Boyd EA, Bero LA. Improving the use of research evidence in guideline
development: 4. managing conﬂicts of interests. Health Research Policy and
Systems 2006;4:16.
[4] Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al.
Development of the AGREE II, part 1: performance, usefulness and areas
for improvement. CMAJ: Canadian Medical Association Journal 2010;182:
1045–52.
[5] Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al.
Development of the AGREE II, part 2: assessment of validity of items and
tools to support application. CMAJ: Canadian Medical Association Journal
2010;182:E472–8.
[6] Brouwers MC, KhoME, BrowmanGP, Burgers JS, Cluzeau F, Feder G, et al. AGREE
II: advancing guideline development, reporting and evaluation in health care.
CMAJ: Canadian Medical Association Journal 2010;182:E839–42.
[7] Edejer TT. Improving the use of research evidence in guideline development:
11. Incorporating considerations of cost-effectiveness, affordability and
resource implications. Health Research Policy and Systems 2006;4:23.
[8] Evidence-Based Medicine Working Group. Evidence-based medicine. A new
approach to teaching the practice of medicine. JAMA: Journal of the American
Medical Association 1992;268:2420–5.
[9] Fretheim A, Schu¨nemann HJ, Oxman AD. Improving the use of research
evidence in guideline development: 3. group composition and consultation
process. Health Research Policy and Systems 2006;4:15.
[10] Fretheim A, Schu¨nemann HJ, Oxman AD. Improving the use of research
evidence in guideline development: 5. group processes. Health Research
Policy and Systems 2006;4:17.
[11] Fretheim A, Schu¨nemann HJ, Oxman AD. Improving the use of research
evidence in guideline development: 15. disseminating and implementing
guidelines. Health Research Policy and Systems 2006;4:27.
[12] Graham ID, Calder LA, He´bert PC, Carter AO, Tetroe JM. A comparison of
clinical practice guideline appraisal instruments. International Journal of
Technology Assessment in Health Care 2000;16:1024–38.
[13] Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, et al. Practical
guidance for the management of aromatase inhibitor-associated bone loss.
Annals of Oncology 2007;9:1407–16.
[14] Oxman AD, Schu¨nemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 2. priority setting. Health Research
Policy and Systems 2006;4:14.
[15] Oxman AD, Schu¨nemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 7. deciding what evidence to include.
Health Research Policy and Systems 2006;4:19.
[16] Oxman AD, Schu¨nemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 8. synthesis and presentation of evi-
dence. Health Research Policy and Systems 2006;4:20.
B. Vincenzi et al. / Journal of Bone Oncology 1 (2012) 30–3434[17] Oxman AD, Schu¨nemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 12. incorporating considerations of
equity. Health Research Policy and Systems 2006;4:24.
[18] Oxman AD, Schu¨nemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 14. reporting guidelines. Health
Research Policy and Systems 2006;4:26.
[19] Oxman AD, Schu¨nemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 16. evaluation. Health Research Policy
and Systems 2006;4:28.
[20] Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence
based medicine: what it is and what it isn’t. BMJ 1996;312:71–2.
[21] Schu¨nemann HJ, Fretheim A, Oxman AD. Improving the use of research
evidence in guideline development: 1. guidelines for guidelines. Health
Research Policy and Systems 2006;4:13.
[22] Schu¨nemann HJ, Oxman AD, Fretheim A. Improving the use of research
evidence in guideline development: 6. determining which outcomes are
important. Health Research Policy and Systems 2006;4:18.
[23] Schu¨nemann HJ, Fretheim A, Oxman AD. Improving the use of research
evidence in guideline development: 9. grading evidence and recommenda-
tions. Health Research Policy and Systems 2006;4:21.[24] Schu¨nemann HJ, Fretheim A, Oxman AD. Improving the use of research
evidence in guideline development: 10. integrating values and consumer
involvement. Health Research Policy and Systems 2006;4:22.
[25] Schu¨nemann HJ, Fretheim A, Oxman AD. Improving the use of research
evidence in guideline development: 13. applicability, transferability and
adaptation. Health Research Policy and Systems 2006;4:25.
[26] Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following
guidelines? The methodological quality of clinical practice guidelines in the
peer-reviewed medical literature JAMA: Journal of the American Medical
Association 1999;281:1900–5.
[27] Vigna-Taglianti F, Vineis P, Liberati A, Faggiano F. Quality of systematic
reviews used in guidelines for oncology practice. Annals of Oncology 2006;17:
691–701.
[28] Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D. A systematic
review of appraisal tools for clinical practice guidelines: multiple similarities
and one common deﬁcit. International Journal for Quality in Health Care
2005;17:235–42.
[29] Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines:
potential beneﬁts, limitations, and harms of clinical guidelines. BMJ 1999;318:
527–30.
